CareLit · DOI-Nachweis · Pneumologie
Impact of epidermal growth factor receptor (EGFR) inhibitors on cisplatin-resistant non-small cell lung cancer (NSCLC) cell lines in parallel to naïve cells at therapeutic doses
DOI 10.1055/s-0035-1556662
Bibliografische Angaben
Nachweis in CareLit
Autor:innenV Pamidiboina, F Tian, K Rosemarie, M Schaule, RM Huber
ZeitschriftPneumologie
Ausgabe07/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Chemotherapy represents the backbone of treatment of advanced NSCLC; a platinum-based doublet is standard in first-line treatment. But resistance limits the effectiveness of anticancer drugs and is the major cause of relapse and cancer mortality. Cisplatin activates membrane-integrated proteins, like the EGFR. As in more than 60% of NSCLC s EGFR is overexpressed and in about 10% activated by a driver m…
Zitieren
Zitierempfehlung
V Pamidiboina, F Tian, K Rosemarie, M Schaule, RM Huber (2015) Impact of epidermal growth factor receptor (EGFR) inhibitors on cisplatin-resistant non-small cell lung cancer (NSCLC) cell lines in parallel to naïve cells at therapeutic doses. Pneumologie (07). https://doi.org/10.1055/s-0035-1556662
Mit CareLit weiterarbeiten